• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

    5.625 -0.175 (-3.02%)
    Streaming Delayed Price Updated: 1:26 PM EDT, Aug 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,952
    Open 5.800
    Bid (Size) 5.550 (100)
    Ask (Size) 5.700 (9,600)
    Prev. Close 5.800
    Today's Range 5.625 - 5.810
    52wk Range 1.900 - 10.59
    Shares Outstanding 620,290
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    New T Cell Therapy Could Transform Glioblastoma Care
    Via Investor Brand Network
    Researchers Identify a Protein That Could Be Targeted in Glioblastoma Therapy
    Via Investor Brand Network

    Performance

    YTD
    +6.1%
    +6.1%
    1 Month
    +10.9%
    +10.9%
    3 Month
    +7.8%
    +7.8%
    6 Month
    +89.4%
    +89.4%
    1 Year
    -14.0%
    -14.0%

    More News

    Read More
    NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 Results as Strategic Pivot Advances
    Via Investor Brand Network
    News headline image
    CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation
    From CNS Pharmaceuticals, Inc.
    Via ACCESS Newswire
    Focused Ultrasound Shows Promise in Treating Brain Tumors
    Via Investor Brand Network
    Collagen Tiles Could Prevent Brain Cancer Recurrence
    Via Investor Brand Network
    Spanish Patient Highlights Risks of Poorly Cooked Pork
    Via Investor Brand Network
    Novel Vitamin B12 Treatment Offers Hope in Brain Cancer Treatment
    Via Investor Brand Network
    Experimental Immunotherapy Offers Hope Against Deadly Pediatric Brain Cancer
    Via Investor Brand Network
    Study Finds No Evidence That Mobile Phones Can Cause Brain Cancer
    Via Investor Brand Network
    Widely Prescribed Thyroid Hormone Could Prevent Pediatric Brain Tumor Recurrence
    Via Investor Brand Network
    New Vaccine Gives Brain Cancer Patients Hope of Longer Survival
    Via Investor Brand Network
    Scientists Find Targeting Enzyme That Could Block Brain Metastases
    Via Investor Brand Network
    WashU Vaccine Could Revolutionize Personalized Glioblastoma Treatment
    Via Investor Brand Network
    Study Links TBI to Higher Mortality Risk Due to Brain Cancer
    Via Investor Brand Network
    InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation
    Via Investor Brand Network
    News headline image
    CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
    Via ACCESS Newswire
    Pediatric Brain Tumors Spread Faster as Immune Cells Build Enabling Scaffolding
    Via Investor Brand Network
    Study Finds Many Young Adults Suffer Sexual Problems After Cancer Treatment
    Via Investor Brand Network
    Study Finds Many Young Adults Suffer Sexual Problems After Cancer Treatment
    Via Investor Brand Network
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    Study Finds That Errors in Brain Cell Division Could Trigger Cancer
    Via Investor Brand Network
    Study Suggests Testosterone Slows Glioblastoma Progression in Men
    Via Investor Brand Network
    MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports First-Quarter 2026 Results, Advances Strategic Transformation
    Via Investor Brand Network
    News headline image
    CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
    Via ACCESS Newswire

    Frequently Asked Questions

    Is CNS Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, CNS Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does CNS Pharmaceuticals, Inc. - Common Stock trade on?
    CNS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for CNS Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for CNS Pharmaceuticals, Inc. - Common Stock is CNSP on the Nasdaq Stock Market
    What is the current price of CNS Pharmaceuticals, Inc. - Common Stock?
    The current price of CNS Pharmaceuticals, Inc. - Common Stock is 5.625
    When was CNS Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of CNS Pharmaceuticals, Inc. - Common Stock was at 08/26/26 01:26 PM ET
    What is the market capitalization of CNS Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of CNS Pharmaceuticals, Inc. - Common Stock is 3.49M
    How many shares of CNS Pharmaceuticals, Inc. - Common Stock are outstanding?
    CNS Pharmaceuticals, Inc. - Common Stock has 3M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.